AVANIR Pharmaceuticals (FRA:AV2B) Cash Flow from Financing : €205.18 Mil (TTM As of Sep. 2014)

AVANIR Pharmaceuticals Cash Flow from Financing Chart

AVANIR Pharmaceuticals Annual Data
	Trend	Sep05	Sep06	Sep07	Sep08	Sep09	Sep10	Sep11	Sep12	Sep13	Sep14
Cash Flow from Financing		Get a 7-Day Free Trial					23.98	73.26	37.88	38.35	208.49

AVANIR Pharmaceuticals Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Cash Flow from Financing	Get a 7-Day Free Trial															22.67	0.02	19.29	34.89	150.97

AVANIR Pharmaceuticals Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

AVANIR Pharmaceuticals's Cash from Financing for the fiscal year that ended in Sep. 2014 is calculated as:

AVANIR Pharmaceuticals's Cash from Financing for the quarter that ended in Sep. 2014 is:

Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €205.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AVANIR Pharmaceuticals  (FRA:AV2B) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

AVANIR Pharmaceuticals's issuance of stock for the three months ended in Sep. 2014 was €168.36 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

AVANIR Pharmaceuticals's repurchase of stock for the three months ended in Sep. 2014 was €0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

AVANIR Pharmaceuticals's net issuance of debt for the three months ended in Sep. 2014 was €-19.03 Mil. AVANIR Pharmaceuticals spent €19.03 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

AVANIR Pharmaceuticals's net issuance of preferred for the three months ended in Sep. 2014 was €0.00 Mil. AVANIR Pharmaceuticals paid €0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

AVANIR Pharmaceuticals's cash flow for dividends for the three months ended in Sep. 2014 was €0.00 Mil. AVANIR Pharmaceuticals received €0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

AVANIR Pharmaceuticals's other financing for the three months ended in Sep. 2014 was €1.64 Mil. AVANIR Pharmaceuticals received €1.64 Mil on other financial activities.

AVANIR Pharmaceuticals Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

AVANIR Pharmaceuticals (FRA:AV2B) Business Description